Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22567028 | 0.85 | — | — | |
| SCHEMBL11954946 | 0.78 | NOTUM (0.43) | NOTUMMAOAMAOBCA12CA1 | |
| SCHEMBL22826930 | 0.71 | NOTUM (0.36) | NOTUMCA1CA2CA9 | |
| SCHEMBL27420039 | 0.71 | MIF (0.39) | — | |
| SCHEMBL20820801 | 0.68 | GRIA4 (0.41) | — | |
| SCHEMBL14212094 | 0.68 | NOTUM (0.41) | NOTUMCA1CA2CA9 | |
| SCHEMBL1412500 | 0.67 | NOTUM (0.45) | NOTUMROCK1CLK4 | |
| SCHEMBL25013966 | 0.67 | MAOA (0.37) | NOTUMMAOAMAOB | |
| SCHEMBL15360299 | 0.67 | DDX3X (0.32) | NOTUM | |
| SCHEMBL12825187 | 0.66 | MAOA (0.42) | NOTUMMAOAMAOBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228728-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| EP-3766981-A1 | CATIONIC POLOXAMERS AND THEIR USE IN TRANSDUCTION | OZ Biosciences (FR) | 2021-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228728-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | DARS1, CD2, FCGR2A | NOTUM 2252/4885MAOA 1688/4885MAOB 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.